Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02421380 · ClinicalTrials.gov registry record · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
A NA study of Malignant Solid Tumors, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 109
- Enrollment target
- 2
- Study locations
NCT02421380: Recruiting NA study of Malignant Solid Tumors, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02421380 is a NA study of Malignant Solid Tumors that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 109 participants, below the 3,358-participant average among 3 other Malignant Solid Tumors trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02421380, a NA study of Malignant Solid Tumors, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 109 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of the study is to test a new approach to see if the test results can be reproduced each time the Magnetic resonance imaging (MRI) is done for an individual patient. The study will explore the use of an imaging agent called hyperpolarized \[1-13C\] pyruvate (HP) with MRI scans. (MRI) is a technique that takes pictures of the body's organs using a magnetic field and radiofrequency waves that cannot be felt. In order to accomplish the goal of the study the patient will have two hyperpolarized MRI scans to assess if scans can be reproduced. The hyperpolarized MRI scans will be compared with the pathological results of the surgery to see if the hyperpolarized MRI provides additional information regarding disease metabolism.
Primary Outcome
The imaging will include standard T2-weighted, diffusion-weighted (DW), dynamic contrast-enhanced (DCE) and 1H MR spectroscopic imaging, depending on the solid tumor type. This multi-parametric data will be used to delineate the tumor as well as compare to HP MRI.
Conditions Studied
Interventions
- DRUG Hyperpolarized Pyruvate
Study Locations (2)
New Jersey
- Memorial Sloan Kettering Bergen (Consent only ) - Montvale
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2015-04 |
| Est. Completion | 2026-04 |
| Phase | NA |
What NCT02421380 shows while recruiting
NCT02421380 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 3,358-participant average among 3 other Malignant Solid Tumors trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Malignant Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Hyperpolarized Pyruvate is the first listed.
NCT02421380 reports a single indexed study location in New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT02421380 about?
NCT02421380 is a clinical study titled "Characterization of Hyperpolarized Pyruvate MRI Reproducibility". The purpose of the study is to test a new approach to see if the test results can be reproduced each time the Magnetic resonance imaging (MRI) is done for an individual patient. The study will explore the use of an imaging agent called hyperpolarized \[1-13C\] pyruvate (HP) with MRI scans. (MRI) is ...
What is the current status of trial NCT02421380?
This trial is currently recruiting. It is a NA study. The enrollment target is 109 participants. The study started on 2015-04. Estimated completion is 2026-04.
What conditions does trial NCT02421380 study?
This clinical trial studies the following conditions: Malignant Solid Tumors.
What interventions are being tested in trial NCT02421380?
The interventions under investigation include: Hyperpolarized Pyruvate (DRUG).
Who is sponsoring clinical trial NCT02421380?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02421380 being conducted?
This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia